| Missing Links? Citation Matrix | Graphs | Glossary HistCite Guide About |
|
MELLIN GW, 1962, NEW ENGL J MED, V267, P1184 MELLIN GW, 1962, NEW ENGL J MED, V267, P1238 LENZ W, 1961, DEUT MED WOCHENSCHR, V86, P2555 LENZ W, 1962, DEUT MED WOCHENSCHR, V87, P1232 KUNZ W, 1956, ARZNEIMITTEL-FORSCH, V6, P426 SHESKIN J, 1965, LEPROSY REV, V36, P183 WIEDEMANN HR, 1961, MED WELT, V37, P1863 BECKMANN R, 1962, ARZNEIMITTEL-FORSCH, V12, P1095 |
Nodes: 2685,
Authors: 6203,
Journals: 662,
Outer References: 16023,
Words: 3995
Collection span: 1956 - 2004
View: Overview. Sorted by LCS.
Page 1: 1 2 3 4 5 6 7 8 9
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
|---|---|---|---|---|---|
| 1 | 14 | 29 | 1160 1994 PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 91(9):4082-4085 DAMATO RJ; LOUGHNAN MS; FLYNN E; FOLKMAN J THALIDOMIDE IS AN INHIBITOR OF ANGIOGENESIS | 326 | 719 |
| 2 | 3 | 25 | 1045 1991 JOURNAL OF EXPERIMENTAL MEDICINE 173(3):699-703 SAMPAIO EP; SARNO EN; GALILLY R; COHN ZA; KAPLAN G THALIDOMIDE SELECTIVELY INHIBITS TUMOR-NECROSIS-FACTOR-ALPHA PRODUCTION BY STIMULATED HUMAN MONOCYTES | 287 | 498 |
| 3 | 10 | 37 | 1588 1999 NEW ENGLAND JOURNAL OF MEDICINE 341(21):1565-1571 Singhal S; Mehta J; Desikan R; Ayers D; Roberson P; Eddlemon P; Munshi N; Anaissie E; Wilson C; Dhodapkar M; Zeldis J; Barlogie B; Siegel D; Crowley J Antitumor activity of thalidomide in refractory multiple myeloma. | 284 | 548 |
| 4 | 1 | 19 | 1100 1993 JOURNAL OF EXPERIMENTAL MEDICINE 177(6):1675-1680 MOREIRA AL; SAMPAIO EP; ZMUIDZINAS A; FRINDT P; SMITH KA; KAPLAN G THALIDOMIDE EXERTS ITS INHIBITORY-ACTION ON TUMOR-NECROSIS-FACTOR-ALPHA BY ENHANCING MESSENGER-RNA DEGRADATION | 231 | 424 |
| 5 | 0 | 0 | 330 1965 CLINICAL PHARMACOLOGY & THERAPEUTICS 6(3):303-& SHESKIN J THALIDOMIDE IN TREATMENT OF LEPRA REACTIONS | 215 | 259 |
| 6 | 0 | 0 | 45 1961 LANCET 2(721):1358-& MCBRIDE WG THALIDOMIDE AND CONGENITAL ABNORMALITIES | 181 | 432 |
| 7 | 9 | 21 | 1070 1992 NEW ENGLAND JOURNAL OF MEDICINE 326(16):1055-1058 VOGELSANG GB; FARMER ER; HESS AD; ALTAMONTE V; BESCHORNER WE; JABS DA; CORIO RL; LEVIN LS; COLVIN OM; WINGARD JR; SANTOS GW THALIDOMIDE FOR THE TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE | 166 | 253 |
| 8 | 23 | 37 | 1444 1998 JOURNAL OF EXPERIMENTAL MEDICINE 187(11):1885-1892 Haslett PAJ; Corral LG; Albert M; Kaplan G Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset | 142 | 177 |
| 9 | 1 | 23 | 1101 1993 JOURNAL OF INFECTIOUS DISEASES 168(2):408-414 SAMPAIO EP; KAPLAN G; MIRANDA A; NERY JAC; MIGUEL CP; VIANA SM; SARNO EN THE INFLUENCE OF THALIDOMIDE ON THE CLINICAL AND IMMUNOLOGICAL MANIFESTATION OF ERYTHEMA-NODOSUM LEPROSUM | 140 | 210 |
| 10 | 0 | 0 | 110 1962 LANCET 1(7219):45-& LENZ W THALIDOMIDE AND CONGENITAL ABNORMALITIES | 122 | 254 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 11 | 24 | 44 | 1380 1997 NEW ENGLAND JOURNAL OF MEDICINE 336(21):1487-1493 Jacobson JM; Greenspan JS; Spritzler J; Ketter N; Fahey JL; Jackson JB; Fox L; Chernoff M; Wu AW; MacPhail LA; Vasquez GJ; Wohl DA Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection | 119 | 191 |
| 12 | 15 | 34 | 1183 1995 CLINICAL AND EXPERIMENTAL IMMUNOLOGY 99(2):160-167 MCHUGH SM; RIFKIN IR; DEIGHTON J; WILSON AB; LACHMANN PJ; LOCKWOOD CM; EWAN PW THE IMMUNOSUPPRESSIVE DRUG THALIDOMIDE INDUCES T-HELPER CELL-TYPE 2 (TH2) AND CONCOMITANTLY INHIBITS TH1 CYTOKINE PRODUCTION IN MITOGEN-STIMULATED AND ANTIGEN-STIMULATED HUMAN PERIPHERAL-BLOOD MONONUCLEAR CELL-CULTURES | 106 | 143 |
| 13 | 1 | 24 | 1112 1993 PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 90(13):5974-5978 MAKONKAWKEYOON S; LIMSONPOBRE RNR; MOREIRA AL; SCHAUF V; KAPLAN G THALIDOMIDE INHIBITS THE REPLICATION OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 | 105 | 184 |
| 14 | 23 | 41 | 1336 1997 EXPERIMENTAL EYE RESEARCH 64(6):971-978 Kenyon BM; Browne F; DAmato RJ Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization | 96 | 149 |
| 15 | 1 | 7 | 316 1965 BRITISH JOURNAL OF PHARMACOLOGY AND CHEMOTHERAPY 25(2):324-& SCHUMACHER H; SMITH RL; WILLIAMS RT METABOLISM OF THALIDOMIDE - SPONTANEOUS HYDROLYSIS OF THALIDOMIDE IN SOLUTION | 89 | 98 |
| 16 | 10 | 31 | 1632 2000 BLOOD 96(9):2943-2950 Hideshima T; Chauhan D; Shima Y; Raje N; Davies FE; Tai YT; Treon SP; Lin B; Schlossman RL; Richardson P; Muller G; Stirling DI; Anderson KC Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy | 89 | 172 |
| 17 | 8 | 19 | 1684 2000 BRITISH JOURNAL OF HAEMATOLOGY 109(1):89-96 Juliusson G; Celsing F; Turesson I; Lenhoff S; Adriansson M; Malm C Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma | 88 | 117 |
| 18 | 11 | 34 | 464 1968 JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY 31(6):543-& FULLERTON PM; OSULLIVA.DJ THALIDOMIDE NEUROPATHY - A CLINICAL ELECTROPHYSIOLOGICAL AND HISTOLOGICAL FOLLOW-UP STUDY | 86 | 129 |
| 19 | 26 | 54 | 784 1982 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 7(3):317-323 BARNHILL RL; MCDOUGALL AC THALIDOMIDE - USE AND POSSIBLE MODE OF ACTION IN REACTIONAL LEPROMATOUS LEPROSY AND IN VARIOUS OTHER CONDITIONS | 84 | 111 |
| 20 | 0 | 168 1962 NEW ENGLAND JOURNAL OF MEDICINE 267(23):1184-1192 MELLIN GW; KATZENSTEIN M THE SAGA OF THALIDOMIDE. NEUROPATHY TO EMBRYOPATHY, WITH CASE REPORTS OF CONGENITAL ANOMALIES | 83 | 169 | |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 21 | 13 | 27 | 1406 1998 BIOCHEMICAL PHARMACOLOGY 55(11):1827-1834 Bauer KS; Dixon SC; Figg WD Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent | 80 | 120 |
| 22 | 1 | 3 | 126 1962 LANCET 1(7235):912-& SOMERS GF THALIDOMIDE AND CONGENITAL ABNORMALITIES | 79 | 168 |
| 23 | 5 | 8 | 804 1983 BRITISH JOURNAL OF DERMATOLOGY 108(4):461-466 KNOP J; BONSMANN G; HAPPLE R; LUDOLPH A; MATZ DR; MIFSUD EJ; MACHER E THALIDOMIDE IN THE TREATMENT OF 60 CASES OF CHRONIC DISCOID LUPUS-ERYTHEMATOSUS | 78 | 109 |
| 24 | 18 | 24 | 993 1989 DRUG METABOLISM AND DISPOSITION 17(4):402-405 CHEN TL; VOGELSANG GB; PETTY BG; BRUNDRETT RB; NOE DA; SANTOS GW; COLVIN OM PLASMA PHARMACOKINETICS AND URINARY-EXCRETION OF THALIDOMIDE AFTER ORAL DOSING IN HEALTHY MALE-VOLUNTEERS | 77 | 81 |
| 25 | 11 | 30 | 1357 1997 JOURNAL OF IMMUNOLOGY 159(10):5157-5161 Moller DR; Wysocka M; Greenlee BM; Ma XJ; Wahl L; Flockhart DA; Trinchieri G; Karp CL Inhibition of IL-12 production by thalidomide | 77 | 114 |
| 26 | 10 | 48 | 1563 1999 JOURNAL OF IMMUNOLOGY 163(1):380-386 Corral LG; Haslett PAJ; Muller GW; Chen R; Wong LM; Ocampo CJ; Patterson RT; Stirling DI; Kaplan G Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha | 77 | 122 |
| 27 | 86 | 101 | 1282 1996 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 35(6):969-979 Tseng S; Pak G; Washenik K; Pomeranz MK; Shupack JL Rediscovering thalidomide: A review of its mechanism of action, side effects, and potential uses | 76 | 114 |
| 28 | 13 | 38 | 1681 2000 BRITISH JOURNAL OF CANCER 82(4):812-817 Eisen T; Boshoff C; Mak I; Sapunar F; Vaughan MM; Pyle L; Johnston SRD; Ahern R; Smith IE; Gore ME Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer | 76 | 127 |
| 29 | 6 | 34 | 1739 2000 JOURNAL OF CLINICAL ONCOLOGY 18(4):708-715 Fine HA; Figg WD; Jaeckle K; Wen PY; Kyritsis AP; Loeffler JS; Levin VA; Black PM; Kaplan R; Pluda JM; Yung WKA Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas | 75 | 147 |
| 30 | 29 | 116 | 101 1962 EXPERIENTIA 18(9):389-& FAIGLE JW; SCHMID K; RIESS W; KEBERLE H METABOLIC FATE OF THALIDOMIDE | 73 | 124 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 31 | 19 | 23 | 1118 1994 ARCHIVES OF DERMATOLOGY 130(1):66-69 OCHONISKY S; VERROUST J; BASTUJIGARIN S; GHERARDI R; REVUZ J THALIDOMIDE NEUROPATHY INCIDENCE AND CLINICOELECTROPHYSIOLOGIC FINDINGS IN 42 PATIENTS | 72 | 95 |
| 32 | 9 | 28 | 1267 1996 IMMUNOPHARMACOLOGY 31(2-3):213-221 Geitz H; Handt S; Zwingenberger K Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade | 70 | 89 |
| 33 | 13 | 25 | 1396 1998 ANNALS OF INTERNAL MEDICINE 128(6):443-+ Hamuryudan V; Mat C; Saip S; Ozyazgan Y; Siva A; Yurdakul S; Zwingenberger K; Yazici H Thalidomide in the treatment of the mucocutaneous lesions of the Behcet syndrome - A randomized, double-blind, placebo-controlled trial | 67 | 126 |
| 34 | 17 | 30 | 878 1985 BRITISH JOURNAL OF DERMATOLOGY 112(4):475-480 WULFF CH; HOYER H; ASBOEHANSEN G; BRODTHAGEN H DEVELOPMENT OF POLYNEUROPATHY DURING THALIDOMIDE THERAPY | 66 | 85 |
| 35 | 9 | 21 | 1830 2001 BLOOD 98(2):492-494 Barlogie B; Desikan R; Eddlemon P; Spencer T; Zeldis J; Munshi N; Badros A; Zangari M; Anaissie E; Epstein J; Shaughnessy J; Ayers D; Spoon D; Tricot G Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients | 66 | 111 |
| 36 | 13 | 25 | 1585 1999 NATURE MEDICINE 5(5):582-585 Parman T; Wiley MJ; Wells PG Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity | 65 | 110 |
| 37 | 34 | 65 | 169 1962 NEW ENGLAND JOURNAL OF MEDICINE 267(24):1238-1244 MELLIN GW; KATZENSTEIN M THE SAGA OF THALIDOMIDE. NEUROPATHY TO EMBRYOPATHY, WITH CASE REPORTS OF CONGENITAL ANOMALIES | 64 | 109 |
| 38 | 0 | 0 | 690 1979 ARCHIVES OF DERMATOLOGY 115(5):636-637 MASCARO JM; LECHA M; TORRAS H THALIDOMIDE IN THE TREATMENT OF RECURRENT, NECROTIC, AND GIANT MUCOCUTANEOUS APHTHAE AND APHTHOSIS | 64 | 78 |
| 39 | 3 | 14 | 518 1971 BULLETIN OF THE WORLD HEALTH ORGANIZATION 45(6):719-& IYER CGS; LANGUILL.J; UEMURA K; TARABINI.G; SUNDARES.T; BECHELLI LM; DOMINGUE.VM; DELASAGU.JT; RAMANUJA.K WHO COORDINATED SHORT-TERM DOUBLE-BLIND TRIAL WITH THALIDOMIDE IN TREATMENT OF ACUTE LEPRA REACTIONS IN MALE LEPROMATOUS PATIENTS | 62 | 72 |
| 40 | 3 | 9 | 20 1961 BRITISH MEDICAL JOURNAL 2(525):855-& FULLERTON PM; KREMER M NEUROPATHY AFTER INTAKE OF THALIDOMIDE (DISTAVAL) | 61 | 87 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 41 | 0 | 0 | 41 1961 DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT 86(52):2555-& LENZ W KINDLICHE MISSBILDUNGEN NACH MEDIKAMENT-EINNAHME WAHREND DER GRAVIDITAT | 60 | 144 |
| 42 | 4 | 18 | 1214 1995 MOLECULAR MEDICINE 1(4):384-397 TRAMONTANA JM; UTAIPAT U; MOLLOY A; AKARASEWI P; BURROUGHS M; MAKONKAWKEYOON S; JOHNSON B; KLAUSNER JD; ROM W; KAPLAN G THALIDOMIDE TREATMENT REDUCES TUMOR-NECROSIS-FACTOR-ALPHA PRODUCTION AND ENHANCES WEIGHT-GAIN IN PATIENTS WITH PULMONARY TUBERCULOSIS | 60 | 130 |
| 43 | 4 | 13 | 317 1965 BRITISH JOURNAL OF PHARMACOLOGY AND CHEMOTHERAPY 25(2):338-& SCHUMACHER H; SMITH RL; WILLIAMS RT METABOLISM OF THALIDOMIDE - FATE OF THALIDOMIDE AND SOME OF ITS HYDROLYSIS PRODUCTS IN VARIOUS SPECIES | 59 | 72 |
| 44 | 14 | 20 | 1037 1991 BRITISH JOURNAL OF HAEMATOLOGY 78(1):23-27 HENEY D; NORFOLK DR; WHEELDON J; BAILEY CC; LEWIS IJ; BARNARD DL THALIDOMIDE TREATMENT FOR CHRONIC GRAFT-VERSUS-HOST DISEASE | 59 | 72 |
| 45 | 0 | 0 | 1056 1992 DRUG SAFETY 7(2):116-134 GUNZLER V THALIDOMIDE IN HUMAN-IMMUNODEFICIENCY-VIRUS (HIV) PATIENTS - A REVIEW OF SAFETY CONSIDERATIONS | 59 | 75 |
| 46 | 3 | 5 | 1832 2001 BLOOD 98(5):1614-1615 Zangari M; Anaissie E; Barlogie B; Badros A; Desikan R; Gopal AV; Morris C; Toor A; Siegel E; Fink L; Tricot G Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy | 59 | 90 |
| 47 | 71 | 96 | 1613 2000 AMERICAN JOURNAL OF MEDICINE 108(6):487-495 Calabrese L; Fleischer AB Thalidomide: Current and potential clinical applications | 58 | 99 |
| 48 | 1 | 8 | 719 1980 ARCHIVES OF DERMATOLOGICAL RESEARCH 269(3):275-280 FAURE M; THIVOLET J; GAUCHERAND M INHIBITION OF PMN LEUKOCYTES CHEMOTAXIS BY THALIDOMIDE | 56 | 66 |
| 49 | 4 | 5 | 992 1989 BRITISH MEDICAL JOURNAL 298(6671):432-432 YOULE M; CLARBOUR J; FARTHING C; CONNOLLY M; HAWKINS D; STAUGHTON R; GAZZARD B TREATMENT OF RESISTANT APHTHOUS ULCERATION WITH THALIDOMIDE IN PATIENTS POSITIVE FOR HIV ANTIBODY | 56 | 103 |
| 50 | 10 | 27 | 1152 1994 LIFE SCIENCES 55(2):77-92 NOGUEIRA AC; NEUBERT R; HELGE H; NEUBERT D THALIDOMIDE AND THE IMMUNE-SYSTEM .3. SIMULTANEOUS UP-REGULATION AND DOWN-REGULATION OF DIFFERENT INTEGRIN RECEPTORS ON HUMAN WHITE BLOOD-CELLS | 56 | 63 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 51 | 19 | 25 | 1181 1995 CHIRALITY 7(1):44-52 ERIKSSON T; BJORKMAN S; ROTH B; FYGE A; HOGLUND P STEREOSPECIFIC DETERMINATION, CHIRAL INVERSION IN-VITRO AND PHARMACOKINETICS IN HUMANS OF THE ENANTIOMERS OF THALIDOMIDE | 56 | 79 |
| 52 | 10 | 28 | 1759 2000 MAYO CLINIC PROCEEDINGS 75(9):897-901 Rajkumar SV; Fonseca R; Dispenzieri A; Lacy MQ; Lust JA; Witzig TE; Kyle RA; Gertz MA; Greipp PR Thalidomide in the treatment of relapsed multiple myeloma | 56 | 85 |
| 53 | 36 | 61 | 853 1984 INTERNATIONAL JOURNAL OF DERMATOLOGY 23(9):598-602 GROSSHANS E; ILLY G THALIDOMIDE THERAPY FOR INFLAMMATORY DERMATOSES | 55 | 62 |
| 54 | 15 | 27 | 997 1989 JOURNAL OF RHEUMATOLOGY 16(2):158-163 GUTIERREZRODRIGUEZ O; STARUSTABACAL P; GUTIERREZMONTES O TREATMENT OF REFRACTORY RHEUMATOID-ARTHRITIS - THE THALIDOMIDE EXPERIENCE | 55 | 72 |
| 55 | 21 | 26 | 1004 1990 ARCHIVES OF DERMATOLOGY 126(7):923-927 REVUZ J; GUILLAUME JC; JANIER M; HANS P; MARCHAND C; SOUTEYRAND P; BONNETBLANC JM; CLAUDY A; DALLAC S; KLENE C; CRICKX B; SANCHOGARNIER H; CHAUMEIL JC CROSSOVER STUDY OF THALIDOMIDE VS PLACEBO IN SEVERE RECURRENT APHTHOUS STOMATITIS | 53 | 100 |
| 56 | 12 | 22 | 1116 1994 ANNALS OF THE RHEUMATIC DISEASES 53(12):828-832 GARDNERMEDWIN JMM; SMITH NJ; POWELL RJ CLINICAL-EXPERIENCE WITH THALIDOMIDE IN THE MANAGEMENT OF SEVERE ORAL AND GENITAL ULCERATION IN CONDITIONS SUCH AS BEHCETS-DISEASE - USE OF NEUROPHYSIOLOGICAL STUDIES TO DETECT THALIDOMIDE NEUROPATHY | 53 | 72 |
| 57 | 1 | 7 | 1683 2000 BRITISH JOURNAL OF HAEMATOLOGY 108(2):391-393 Kneller A; Raanani P; Hardan I; Avigdor A; Levi I; Berkowicz M; Ben-Bassat I Therapy with thalidomide in refractory multiple myeloma patients - the revival of an old drug | 53 | 75 |
| 58 | 1 | 19 | 6 1960 BRITISH JOURNAL OF PHARMACOLOGY AND CHEMOTHERAPY 15(1):111-116 SOMERS GF PHARMACOLOGICAL PROPERTIES OF THALIDOMIDE (ALPHA-PHTHALIMIDO GLUTARIMIDE) - NEW SEDATIVE HYPNOTIC DRUG | 52 | 71 |
| 59 | 6 | 25 | 1175 1995 BLOOD 86(9):3604-3609 PARKER PM; CHAO N; NADEMANEE A; ODONNELL MR; SCHMIDT GM; SNYDER DS; STEIN AS; SMITH EP; MOLINA A; STEPAN DE; KASHYAP A; PLANAS I; SPIELBERGER R; SOMLO G; MARGOLIN K; ZWINGENBERGER K; WILSMAN K; NEGRIN RS; LONG GD; NILAND JC; BLUME KG; FORMAN SJ THALIDOMIDE AS SALVAGE THERAPY FOR CHRONIC GRAFT-VERSUS-HOST DISEASE | 51 | 85 |
| 60 | 6 | 33 | 1276 1996 JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY 11(3):247-257 Klausner JD; Makonkawkeyoon S; Akarasewi P; Nakata K; Kasinrerk W; Corral L; Dewar RL; Lane HC; Freedman VH; Kaplan G The effect of thalidomide on the pathogenesis of human immunodeficiency virus type 1 and M-tuberculosis infection | 51 | 125 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 61 | 2 | 7 | 901 1985 LEPROSY REVIEW 56(1):35-39 GAD SM; SHANNON EJ; KROTOSKI WA; HASTINGS RC THALIDOMIDE INDUCES IMBALANCES IN LYMPHOCYTE-T SUB-POPULATIONS IN THE CIRCULATING BLOOD OF HEALTHY-MALES | 50 | 65 |
| 62 | 5 | 12 | 320 1965 BRITISH MEDICAL JOURNAL 2(5463):687-& HELLMANN K; DUKE DI; TUCKER DF PROLONGATION OF SKIN HOMOGRAFT SURVIVAL BY THALIDOMIDE | 49 | 73 |
| 63 | 6 | 38 | 1226 1996 AIDS 10(13):1501-1507 ReyesTeran G; SierraMadero JG; delCerro VM; ArroyoFigueroa H; Pasquetti A; Calva JJ; RuizPalacios GM Effects of thalidomide on HIV-associated wasting syndrome: A randomized, double-blind, placebo-controlled clinical trial | 49 | 97 |
| 64 | 5 | 15 | 97 1962 DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT 87(24):1232-& LENZ W; KNAPP K DIE THALIDOMID-EMBRYOPATHIE | 48 | 144 |
| 65 | 10 | 24 | 762 1981 PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES 78(4):2545-2548 GORDON GB; SPIELBERG SP; BLAKE DA; BALASUBRAMANIAN V THALIDOMIDE TERATOGENESIS - EVIDENCE FOR A TOXIC ARENE OXIDE METABOLITE | 48 | 89 |
| 66 | 17 | 44 | 1205 1995 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 32(5):866-869 CARLESIMO M; GIUSTINI S; ROSSI A; BONACCORSI P; CALVIERI S TREATMENT OF CUTANEOUS AND PULMONARY SARCOIDOSIS WITH THALIDOMIDE | 48 | 84 |
| 67 | 8 | 17 | 1589 1999 NEW ENGLAND JOURNAL OF MEDICINE 341(21):1606-1609 Raje N; Anderson K Thalidomide - A revival story. | 48 | 87 |
| 68 | 9 | 18 | 1829 2001 BLOOD 98(1):210-216 Davies FE; Raje N; Hideshima T; Lentzsch S; Young G; Tai YT; Lin B; Podar K; Gupta D; Chauhan D; Treon SP; Richardson PG; Schlossman RL; Morgan GJ; Muller GW; Stirling DI; Anderson KC Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma | 48 | 91 |
| 69 | 3 | 13 | 226 1963 LANCET 1(727):249-& ROATH S; ELVES MW; ISRAELS MCG EFFECTS OF THALIDOMIDE AND ITS DERIVATIVES ON HUMAN LEUCOCYTES CULTURED IN VITRO | 47 | 66 |
| 70 | 22 | 55 | 717 1980 ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE 107(6):515-523 SAMSOEN M; GROSSHANS E; BASSET A THALIDOMIDE IN THE TREATMENT OF DISCOID LUPUS-ERYTHEMATOSUS (DLE) | 47 | 55 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 71 | 8 | 20 | 935 1986 TRANSPLANTATION 41(5):644-647 VOGELSANG GB; HESS AD; GORDON G; SANTOS GW TREATMENT AND PREVENTION OF ACUTE GRAFT-VERSUS-HOST DISEASE WITH THALIDOMIDE IN A RAT MODEL | 47 | 71 |
| 72 | 12 | 24 | 844 1984 ARTHRITIS AND RHEUMATISM 27(10):1118-1121 GUTIERREZRODRIGUEZ O THALIDOMIDE - A PROMISING NEW TREATMENT FOR RHEUMATOID-ARTHRITIS | 46 | 55 |
| 73 | 21 | 33 | 1095 1993 CLINICAL AND EXPERIMENTAL RHEUMATOLOGY 11(5):487-493 ATRA E; SATO EI TREATMENT OF THE CUTANEOUS LESIONS OF SYSTEMIC LUPUS-ERYTHEMATOSUS WITH THALIDOMIDE | 46 | 64 |
| 74 | 7 | 67 | 727 1980 INTERNATIONAL JOURNAL OF DERMATOLOGY 19(6):318-322 SHESKIN J THE TREATMENT OF LEPRA REACTION IN LEPROMATOUS LEPROSY - 15 YEARS EXPERIENCE WITH THALIDOMIDE | 45 | 57 |
| 75 | 7 | 21 | 467 1968 JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS 160(1):201-& SCHUMACHER H; BLAKE DA; GILLETTE JR DISPOSITION OF THALIDOMIDE IN RABBITS AND RATS | 44 | 54 |
| 76 | 21 | 33 | 1543 1999 GASTROENTEROLOGY 117(6):1271-1277 Ehrenpreis ED; Kane SV; Cohen LB; Cohen RD; Hanauer SB Thalidomide therapy for patients with refractory Crohn's disease: An open-label trial | 44 | 131 |
| 77 | 13 | 67 | 1740 2000 JOURNAL OF CLINICAL ONCOLOGY 18(13):2593-2602 Little RF; Wyvill KM; Pluda JM; Welles L; Marshall V; Figg WD; Newcomb FM; Tosato G; Feigal E; Steinberg SM; Whitby D; Goedert JJ; Yarchoan R Activity of thalidomide in AIDS-related Kaposis's sarcoma | 44 | 82 |
| 78 | 3 | 4 | 1985 2001 NEW ENGLAND JOURNAL OF MEDICINE 344(25):1951-1952 Osman K; Comenzo R; Rajkumar SV Deep venous thrombosis and thalidomide therapy for multiple myeloma. | 44 | 57 |
| 79 | 0 | 0 | 7 1960 BRITISH MEDICAL JOURNAL 2(DEC31):1954-1954 FLORENCE AL IS THALIDOMIDE TO BLAME | 43 | 51 |
| 80 | 6 | 9 | 1060 1992 JOURNAL OF CHROMATOGRAPHY-BIOMEDICAL APPLICATIONS 582(1-2):211-216 ERIKSSON T; BJORKMAN S; FYGE A; EKBERG H DETERMINATION OF THALIDOMIDE IN PLASMA AND BLOOD BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY - AVOIDING HYDROLYTIC DEGRADATION | 43 | 43 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 81 | 8 | 21 | 1286 1996 MOLECULAR MEDICINE 2(4):506-515 Corral LG; Muller GW; Moreira AL; Chen YX; Wu MD; Stirling D; Kaplan G Selection of novel analogs of thalidomide with enhanced tumor necrosis factor alpha inhibitory activity | 43 | 62 |
| 82 | 19 | 40 | 1544 1999 GASTROENTEROLOGY 117(6):1278-1287 Vasiliauskas EA; Kam LY; Abreu-Martin MT; Hassard PV; Papadakis KA; Yang HY; Zeldis JB; Targan SR An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease | 43 | 129 |
| 83 | 2 | 2 | 134 1962 LANCET 2(7249):249-& KNAPP V; CHRISTIE GA; SELLER MJ THALIDOMIDE AND CONGENITAL ABNORMALITIES | 42 | 68 |
| 84 | 2 | 4 | 775 1982 ARCHIVES OF DERMATOLOGY 118(8):536-536 SAYLAN T; SALTIK I THALIDOMIDE IN THE TREATMENT OF BEHCETS SYNDROME | 42 | 58 |
| 85 | 22 | 39 | 855 1984 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 11(5):814-819 BARNHILL RL; DOLL NJ; MILLIKAN LE; HASTINGS RC STUDIES ON THE ANTI-INFLAMMATORY PROPERTIES OF THALIDOMIDE - EFFECTS ON POLYMORPHONUCLEAR LEUKOCYTES AND MONOCYTES | 42 | 48 |
| 86 | 2 | 12 | 404 1966 NATURE 211(5055):1308-& FIELD EO; GIBBS JE; TUCKER DF; HELLMANN K EFFECT OF THALIDOMIDE ON GRAFT VERSUS HOST REACTION | 41 | 48 |
| 87 | 6 | 20 | 842 1984 ARCHIVES OF DERMATOLOGY 120(3):338-341 CLEMMENSEN OJ; OLSEN PZ; ANDERSEN KE THALIDOMIDE NEUROTOXICITY | 41 | 59 |
| 88 | 0 | 13 | 1 1956 ARZNEIMITTEL-FORSCHUNG-DRUG RESEARCH 6(8):426-430 KUNZ W; KELLER H; MUCKTER H N-PHTHALYL-GLUTAMINIC IMIDE | 40 | 76 |
| 89 | 31 | 61 | 983 1988 TERATOLOGY 38(3):229-239 STEPHENS TD PROPOSED MECHANISMS OF ACTION IN THALIDOMIDE EMBRYOPATHY | 40 | 63 |
| 90 | 50 | 89 | 1087 1993 ARCHIVES OF TOXICOLOGY 67(1):1-17 NEUBERT R; NOGUEIRA AC; NEUBERT D THALIDOMIDE DERIVATIVES AND THE IMMUNE-SYSTEM .1. CHANGES IN THE PATTERN OF INTEGRIN RECEPTORS AND OTHER SURFACE-MARKERS ON LYMPHOCYTE-T SUBPOPULATIONS OF MARMOSET BLOOD | 40 | 49 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 91 | 13 | 17 | 1051 1991 TRANSPLANTATION 52(5):908-910 KEENAN RJ; EIRAS G; BURCKART GJ; STUART RS; HARDESTY RL; VOGELSANG G; GRIFFITH BP; ZEEVI A IMMUNOSUPPRESSIVE PROPERTIES OF THALIDOMIDE - INHIBITION OF INVITRO LYMPHOCYTE-PROLIFERATION ALONE AND IN COMBINATION WITH CYCLOSPORINE OR FK506 | 39 | 44 |
| 92 | 8 | 13 | 1159 1994 POSTGRADUATE MEDICAL JOURNAL 70(830):901-904 POWELL RJ; GARDNERMEDWIN JMM GUIDELINE FOR THE CLINICAL USE AND DISPENSING OF THALIDOMIDE | 39 | 53 |
| 93 | 10 | 36 | 1254 1996 CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY 81(3):219-223 Klausner JD; Freedman VH; Kaplan G Thalidomide as an anti-TNF-alpha inhibitor: Implications for clinical use | 39 | 56 |
| 94 | 13 | 32 | 1293 1996 PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 93(15):7552-7556 Turk BE; Jiang H; Liu JO Binding of thalidomide to alpha(1)-acid glyeoprotein may be involved in its inhibition of tumor necrosis factor alpha production | 39 | 47 |
| 95 | 13 | 27 | 1437 1998 GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY 236(6):461-466 Kruse FE; Joussen AM; Rohrschneider K; Becker MD; Volcker HE Thalidomide inhibits corneal angiogenesis induced by vascular endothelial growth factor | 39 | 57 |
| 96 | 8 | 28 | 1462 1998 LANCET 352(9140):1586-1589 Wolkenstein P; Latarjet J; Roujeau JC; Duguet C; Boudeau S; Vaillant L; Maignan M; Schuhmacher MH; Milpied B; Pilorget A; Bocquet H; Brun-Buisson C; Revuz J Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis | 39 | 78 |
| 97 | 0 | 344 1965 LEPROSY REVIEW 36:183-187 SHESKIN J Further observations with thalidomide in lepra reactions | 38 | 52 | |
| 98 | 2 | 8 | 980 1988 TERATOLOGY 38(3):203-215 LENZ W A SHORT HISTORY OF THALIDOMIDE EMBRYOPATHY | 38 | 69 |
| 99 | 27 | 38 | 1186 1995 CLINICAL INFECTIOUS DISEASES 20(2):250-254 PATERSON DL; GEORGHIOU PR; ALLWORTH AM; KEMP RJ THALIDOMIDE AS TREATMENT OF REFRACTORY APHTHOUS ULCERATION RELATED TO HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION | 38 | 60 |
| 100 | 27 | 40 | 1741 2000 JOURNAL OF CLINICAL ONCOLOGY 18(14):2710-2717 Baidas SM; Winer EP; Fleming GF; Harris L; Pluda JM; Crawford JG; Yamauchi H; Isaacs C; Hanfelt J; Tefft M; Flockhart D; Johnson MD; Hawkins MJ; Lippman ME; Hayes DF Phase II evaluation of thalidomide in patients with metastatic breast cancer | 38 | 53 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 101 | 0 | 9 | 49 1961 Med Welt 37:1863-1866 WIEDEMANN HR Indications of a current increase of hypoplastic and aplastic deformities of the extremities | 37 | 86 |
| 102 | 6 | 18 | 102 1962 JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION 180(13):1106-& TAUSSIG HB A STUDY OF GERMAN OUTBREAK OF PHOCOMELIA - THALIDOMIDE SYNDROME | 37 | 127 |
| 103 | 6 | 17 | 1532 1999 CLINICAL THERAPEUTICS 21(2):319-330 Zeldis JB; Williams BA; Thomas SD; Elsayed ME STEPS (TM): A comprehensive program for controlling and monitoring access to thalidomide | 37 | 45 |
| 104 | 12 | 43 | 1303 1997 AIDS RESEARCH AND HUMAN RETROVIRUSES 13(10):857-863 Moreira AL; Corral LG; Ye WG; Johnson B; Stirling D; Muller GW; Freedman VH; Kaplan G Thalidomide and thalidomide analogs reduce HIV type 1 replication in human macrophages in vitro | 36 | 47 |
| 105 | 7 | 25 | 1304 1997 AIDS RESEARCH AND HUMAN RETROVIRUSES 13(12):1047-1054 Haslett P; Hempstead M; Seidman C; Diakun J; Vasquez D; Freedman VH; Kaplan G The metabolic and immunologic effects of short-term thalidomide treatment of patients infected with the human immunodeficiency virus | 36 | 57 |
| 106 | 19 | 23 | 1319 1997 BRITISH JOURNAL OF RHEUMATOLOGY 36(3):353-359 Stevens RJ; Andujar C; Edwards CJ; Ames PRJ; Barwick AR; Khamashta MA; Hughes GRV Thalidomide in the treatment of the cutaneous manifestations of lupus erythematosus: Experience in sixteen consecutive patients | 36 | 49 |
| 107 | 21 | 33 | 1439 1998 IMMUNOPHARMACOLOGY 40(1):11-20 Rowland TL; McHugh SM; Deighton J; Dearman RJ; Ewan PW; Kimber I Differential regulation by thalidomide and dexamethasone of cytokine expression in human peripheral blood mononuclear cells | 36 | 48 |
| 108 | 43 | 52 | 1549 1999 IMMUNOLOGY TODAY 20(12):538-540 Marriott JB; Muller G; Dalgleish AG Thalidomide as an emerging immunotherapeutic agent | 36 | 45 |
| 109 | 0 | 189 1963 ARZNEIMITTEL-FORSCHUNG 13:185-191 BECKMANN R The behavior of thalidomide in the human and animal organism. part 2. | 35 | 47 | |
| 110 | 7 | 10 | 720 1980 ARCHIVES OF DERMATOLOGY 116(5):571-572 VANDENBROEK H TREATMENT OF PRURIGO NODULARIS WITH THALIDOMIDE | 35 | 48 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 111 | 17 | 35 | 843 1984 ARCHIVES OF DERMATOLOGY 120(11):1466-1470 ARONSON IK; YU R; WEST DP; VANDENBROEK H; ANTEL J THALIDOMIDE-INDUCED PERIPHERAL NEUROPATHY - EFFECT OF SERUM FACTOR ON NERVE CULTURES | 34 | 38 |
| 112 | 10 | 25 | 1199 1995 IMMUNOPHARMACOLOGY 31(1):109-116 SHANNON EJ; SANDOVAL F THALIDOMIDE INCREASES THE SYNTHESIS OF IL-2 IN CULTURES OF HUMAN MONONUCLEAR-CELLS STIMULATED WITH CONCANAVALIN-A, STAPHYLOCOCCAL-ENTEROTOXIN-A, AND PURIFIED PROTEIN DERIVATIVE | 34 | 37 |
| 113 | 2 | 5 | 1367 1997 LANCET 350(9089):1445-1446 Wettstein AR; Meagher AP Thalidomide in Crohn's disease | 34 | 52 |
| 114 | 5 | 6 | 117 1962 LANCET 1(7224):303-& SPEIRS AL THALIDOMIDE AND CONGENITAL ABNORMALITIES | 33 | 76 |
| 115 | 83 | 215 | 1277 1996 JOURNAL OF INFLAMMATION 46(4):177-211 Zwingenberger K; Wnendt S Immunomodulation by thalidomide: Systematic review of the literature and of unpublished observations | 33 | 38 |
| 116 | 17 | 26 | 1279 1996 JOURNAL OF MEDICINAL CHEMISTRY 39(17):3238-3240 Muller GW; Corral LG; Shire MG; Wang H; Moreira A; Kaplan G; Stirling DI Structural modifications of thalidomide produce analogs with enhanced tumor necrosis factor inhibitory activity | 33 | 48 |
| 117 | 14 | 30 | 1445 1998 JOURNAL OF IMMUNOLOGY 161(8):4236-4243 Marriott JB; Westby M; Cookson S; Guckian M; Goodbourn S; Muller G; Shire MG; Stirling D; Dalgleish AG CC-3052: A water-soluble analog of thalidomide and potent inhibitor of activation-induced TNF-alpha production | 33 | 49 |
| 118 | 19 | 28 | 1570 1999 JOURNAL OF PHARMACEUTICAL SCIENCES 88(1):121-125 Figg WD; Raje S; Bauer KS; Tompkins A; Venzon D; Bergan R; Chen A; Hamilton M; Pluda J; Reed E Pharmacokinetics of thalidomide in an elderly prostate cancer population | 33 | 47 |
| 119 | 1 | 4 | 651 1977 LANCET 1(8005):251-251 ERAVELLY J; WATERS MFR THALIDOMIDE IN WEBER-CHRISTIAN DISEASE | 32 | 37 |
| 120 | 4 | 36 | 765 1981 SCANDINAVIAN JOURNAL OF IMMUNOLOGY 13(6):553-562 SHANNON EJ; MIRANDA RO; MORALES MJ; HASTINGS RC INHIBITION OF DENOVO IGM ANTIBODY-SYNTHESIS BY THALIDOMIDE AS A RELEVANT MECHANISM OF ACTION IN LEPROSY | 32 | 41 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 121 | 4 | 4 | 970 1988 LANCET 1(8577):117-117 LIM SH; MCWHANNELL A; VORA AJ; BOUGHTON BJ SUCCESSFUL TREATMENT WITH THALIDOMIDE OF ACUTE GRAFT-VERSUS-HOST DISEASE AFTER BONE-MARROW TRANSPLANTATION | 32 | 35 |
| 122 | 11 | 27 | 1069 1992 LIFE SCIENCES 51(26):2107-2116 NEUBERT R; NOGUEIRA AC; NEUBERT D THALIDOMIDE AND THE IMMUNE-SYSTEM .2. CHANGES IN RECEPTORS ON BLOOD-CELLS OF A HEALTHY VOLUNTEER | 32 | 38 |
| 123 | 5 | 20 | 890 1985 INTERNATIONAL JOURNAL OF LEPROSY AND OTHER MYCOBACTERIAL DISEASES 53(2):201-205 MONCADA B; BARANDA ML; GONZALEZAMARO R; URBINA R; LOREDO CE THALIDOMIDE - EFFECT ON T-CELL SUBSETS AS A POSSIBLE MECHANISM OF ACTION | 31 | 42 |
| 124 | 11 | 19 | 963 1988 BONE MARROW TRANSPLANTATION 3(5):393-398 VOGELSANG GB; HESS AD; SANTOS GW THALIDOMIDE FOR TREATMENT OF GRAFT-VERSUS-HOST DISEASE | 31 | 38 |
| 125 | 4 | 6 | 1103 1993 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 28(2):271-272 GHIGLIOTTI G; REPETTO T; FARRIS A; ROY MT; DEMARCHI R THALIDOMIDE - TREATMENT OF CHOICE FOR APHTHOUS ULCERS IN PATIENTS SEROPOSITIVE FOR HUMAN-IMMUNODEFICIENCY-VIRUS | 31 | 39 |
| 126 | 28 | 53 | 1955 2001 JOURNAL OF BIOLOGICAL CHEMISTRY 276(25):22382-22387 Keifer JA; Guttridge DC; Ashburner BP; Baldwin AS Inhibition of NF-kappa B activity by thalidomide through suppression of I kappa B kinase activity | 31 | 54 |
| 127 | 2 | 6 | 442 1967 NATURE 215(5098):296-& FABRO S; SMITH RL; WILLIAMS RT TOXICITY AND TERATOGENICITY OF OPTICAL ISOMERS OF THALIDOMIDE | 30 | 58 |
| 128 | 8 | 22 | 501 1970 CLINICAL PHARMACOLOGY & THERAPEUTICS 11(4):481-& HASTINGS RC; TRAUTMAN JR; ENNA CD; JACOBSON RR THALIDOMIDE IN TREATMENT OF ERYTHEMA NODOSUM LEPROSUM - WITH A NOTE ON SELECTED LABORATORY ABNORMALITIES IN ERYTHEMA NODOSUM LEPROSUM | 30 | 40 |
| 129 | 3 | 8 | 779 1982 BRITISH JOURNAL OF DERMATOLOGY 107(1):83-86 NAAFS B; BAKKERS EJM; FLINTERMAN J; FABER WR THALIDOMIDE TREATMENT OF SUB-ACUTE CUTANEOUS LUPUS-ERYTHEMATOSUS | 30 | 44 |
| 130 | 26 | 33 | 1140 1994 EUROPEAN JOURNAL OF DERMATOLOGY 4(1):9-15 OCHONISKY S; REVUZ J THALIDOMIDE USE IN DERMATOLOGY | 29 | 34 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 131 | 10 | 18 | 1235 1996 ANTI-CANCER DRUGS 7(3):339-343 Minchinton AI; Fryer KH; Wendt KR; Clow KA; Hayes MMM The effect of thalidomide on experimental tumors and metastases | 29 | 50 |
| 132 | 7 | 11 | 1584 1999 NATURE MEDICINE 5(5):489-490 Hales BF Thalidomide on the comeback trail | 29 | 31 |
| 133 | 22 | 98 | 1690 2000 CANCER TREATMENT REVIEWS 26(5):351-362 Rajkumar SV; Witzig TE A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma | 29 | 53 |
| 134 | 5 | 13 | 1811 2001 ANNALS OF ONCOLOGY 12(7):991-995 Dimopoulos MA; Zervas K; Kouvatseas G; Galani E; Grigoraki V; Kiamouris C; Vervessou E; Samantas E; Papadimitriou C; Economou O; Gika D; Panayiotidis P; Christakis I; Anagnostopoulos N Thalidomide and dexamethasone combination for refractory multiple myeloma | 29 | 40 |
| 135 | 22 | 37 | 2226 2002 JOURNAL OF CLINICAL ONCOLOGY 20(21):4319-4323 Rajkumar SV; Hayman S; Gertz MA; Dispenzieri A; Lacy MQ; Greipp PR; Geyer S; Iturria N; Fonseca R; Lust JA; Kyle RA; Witzig TE Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma | 29 | 52 |
| 136 | 7 | 22 | 2476 2003 JOURNAL OF CLINICAL ONCOLOGY 21(1):16-19 Weber D; Rankin K; Gavino M; Delasalle K; Alexanian R Thalidomide alone or with dexamethasone for previously untreated multiple myeloma | 29 | 55 |
| 137 | 0 | 1 | 145 1962 LANCET 2(7258):724-& FELISATI D; KNAPP VI THALIDOMIDE AND CONGENITAL ABNORMALITIES | 28 | 47 |
| 138 | 3 | 10 | 395 1966 LANCET 1(7447):1134-& TURK JL; HELLMANN K; DUKE DI EFFECT OF THALIDOMIDE ON IMMUNOLOGICAL RESPONSE IN LOCAL LYMPH NODES AFTER A SKIN HOMOGRAFT | 28 | 32 |
| 139 | 0 | 0 | 613 1975 HAUTARZT 26(4):215-215 SHESKIN J THERAPY OF PRURIGO NODULARIS HYDE WITH THALIDOMIDE | 28 | 30 |
| 140 | 6 | 28 | 1442 1998 INTERNATIONAL JOURNAL OF STD & AIDS 9(12):751-755 Fife K; Howard MR; Gracie F; Phillips RH; Bower M Activity of thalidomide in AIDS-related Kaposi's sarcoma and correlation with HHV8 titre | 28 | 44 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 141 | 12 | 59 | 1831 2001 BLOOD 98(4):958-965 Raza A; Meyer P; Dutt D; Zorat F; Lisak L; Nascimben F; du Randt M; Kaspar C; Goldberg C; Loew J; Dar S; Gezer S; Venugopal P; Zeldis J Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes | 28 | 60 |
| 142 | 10 | 19 | 1975 2001 LEUKEMIA 15(8):1274-1276 Rajkumar SV; Dispenzieri A; Fonseca R; Lacy MQ; Geyer S; Lust JA; Kyle RA; Greipp PR; Gertz MA; Witzig TE Thalidomide for previously untreated indolent or smoldering multiple myeloma | 28 | 43 |
| 143 | 1 | 4 | 692 1979 BRITISH MEDICAL JOURNAL 1(6166):792-792 WATERS MFR; LAING ABG; AMBIKAPATHY A; LENNARDJONES JE TREATMENT OF ULCERATIVE-COLITIS WITH THALIDOMIDE | 27 | 36 |
| 144 | 16 | 24 | 886 1985 INTERNATIONAL JOURNAL OF DERMATOLOGY 24(2):131-134 NAAFS B; FABER WR THALIDOMIDE THERAPY - AN OPEN TRIAL | 27 | 36 |
| 145 | 3 | 15 | 934 1986 TOXICOLOGY AND APPLIED PHARMACOLOGY 82(1):175-179 BRAUN AG; HARDING FA; WEINREB SL TERATOGEN METABOLISM - THALIDOMIDE ACTIVATION IS MEDIATED BY CYTOCHROME-P-450 | 27 | 34 |
| 146 | 5 | 7 | 1065 1992 LANCET 339(8792):549-550 BESSIS D; GUILLOT B; MONPOINT S; DANDURAND M; GUILHOU JJ THALIDOMIDE FOR SYSTEMIC LUPUS-ERYTHEMATOSUS | 27 | 31 |
| 147 | 15 | 22 | 1253 1996 CHIRALITY 8(5):390-396 Wnendt S; Finkam M; Winter W; Ossig J; Raabe G; Zwingenberger K Enantioselective inhibition of TNF-alpha release by thalidomide and thalidomide-analogues | 27 | 33 |
| 148 | 12 | 39 | 1482 1999 AIDS RESEARCH AND HUMAN RETROVIRUSES 15(13):1169-1179 Haslett PAJ; Klausner JD; Makonkawkeyoon S; Moreira A; Metatratip P; Boyle B; Kunachiwa W; Maneekarn N; Vongchan P; Corral LG; Elbeik T; Shen Z; Kaplan G Thalidomide stimulates T cell responses and interleukin 12 production in HIV-infected patients | 27 | 33 |
| 149 | 6 | 17 | 1564 1999 JOURNAL OF INFECTIOUS DISEASES 180(1):61-67 Jacobson JM; Spritzler J; Fox L; Fahey JL; Jackson JB; Chernoff M; Wohl DA; Wu AW; Hooton TM; Sha BE; Shikuma CM; MacPhail LA; Simpson DM; Trapnell CB; Basgoz N; Natl Inst Allergy Infect Dis AIDS Clin Trials G Thalidomide for the treatment of esophageal aphthous ulcers in patients with human immunodeficiency virus infection | 27 | 38 |
| 150 | 54 | 120 | 1707 2000 DRUGS 60(2):273-292 Peuckmann V; Fisch M; Bruera E Potential novel uses of thalidomide - Focus on palliative care | 27 | 40 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 151 | 7 | 21 | 318 1965 BRITISH JOURNAL OF PHARMACOLOGY AND CHEMOTHERAPY 25(2):352-& FABRO S; SCHUMACHER H; SMITH RL; STAGG RBL; WILLIAMS RT METABOLISM OF THALIDOMIDE-SOME BIOLOGICAL EFFECTS OF THALIDOMIDE AND ITS METABOLITES | 26 | 31 |
| 152 | 12 | 28 | 923 1986 JOURNAL OF NEUROLOGY 233(2):83-89 HESS CW; HUNZIKER T; KUPFER A; LUDIN HP THALIDOMIDE-INDUCED PERIPHERAL NEUROPATHY - A PROSPECTIVE CLINICAL, NEUROPHYSIOLOGICAL AND PHARMACOGENETIC EVALUATION | 26 | 30 |
| 153 | 3 | 5 | 971 1988 LANCET 1(8581):359-359 SAURAT JH; CAMENZIND M; HELG C; CHAPUIS B THALIDOMIDE FOR GRAFT-VERSUS-HOST DISEASE AFTER BONE-MARROW TRANSPLANTATION | 26 | 31 |
| 154 | 1 | 4 | 1047 1991 LANCET 337(8738):436-437 WILLIAMS I; WELLER IVD; MALIN A; ANDERSON J; WATERS MFR THALIDOMIDE HYPERSENSITIVITY IN AIDS | 26 | 34 |
| 155 | 6 | 11 | 1120 1994 BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS 199(2):455-460 NISHIMURA K; HASHIMOTO Y; IWASAKI S ENHANCEMENT OF PHORBOL ESTER-INDUCED PRODUCTION OF TUMOR-NECROSIS-FACTOR-ALPHA BY THALIDOMIDE | 26 | 43 |
| 156 | 14 | 23 | 1417 1998 BONE MARROW TRANSPLANTATION 21(6):577-581 Rovelli A; Arrigo C; Nesi F; Balduzzi A; Nicolini B; Locasiulli A; Vassallo E; Miniero R; Uderzo C The role of thalidomide in the treatment of refractory chronic graft-versus-host disease following bone marrow transplantation in children | 26 | 36 |
| 157 | 11 | 34 | 84 1962 BRITISH MEDICAL JOURNAL 2(5296):14-& LECK IM; MILLAR ELM INCIDENCE OF MALFORMATIONS SINCE INTRODUCTION OF THALIDOMIDE | 25 | 64 |
| 158 | 1 | 3 | 111 1962 LANCET 1(7219):45-& PFEIFFER RA; KOSENOW W THALIDOMIDE AND CONGENITAL ABNORMALITIES - REPLY | 25 | 44 |
| 159 | 1 | 7 | 149 1962 LANCET 2(7260):836-& KEMPER FH THALIDOMIDE AND CONGENITAL ABNORMALITIES | 25 | 36 |
| 160 | 1 | 6 | 175 1962 PROCEEDINGS OF THE SOCIETY FOR EXPERIMENTAL BIOLOGY AND MEDICINE 109(3):511-& MACKENZIE RD; MCGRATH WR ABSORPTION OF THALIDOMIDE IN RAT | 25 | 29 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 161 | 3 | 12 | 261 1963 SCIENCE 139(355):110-& FRANK O; LEEVY CM; HUTNER SH; BAKER H; ZIFFER H; AARONSON S METABOLIC DEFICIENCIES IN PROTOZOA INDUCED BY THALIDOMIDE | 25 | 43 |
| 162 | 8 | 13 | 303 1964 SCIENCE 146(364):1300-& DELAHUNT CS; LASSEN LJ THALIDOMIDE SYNDROME IN MONKEYS | 25 | 60 |
| 163 | 7 | 11 | 859 1984 LANCET 2(8417):1424-1426 JENKINS JS; POWELL RJ; ALLEN BR; LITTLEWOOD SM; MAURICE PDL; SMITH NJ THALIDOMIDE IN SEVERE OROGENITAL ULCERATION | 25 | 35 |
| 164 | 10 | 18 | 892 1985 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 12(1):85-90 GRINSPAN D SIGNIFICANT RESPONSE OF ORAL APHTHOSIS TO THALIDOMIDE TREATMENT | 25 | 42 |
| 165 | 5 | 19 | 912 1986 ARCHIVES OF INTERNAL MEDICINE 146(5):878-881 JORIZZO JL; SCHMALSTIEG FC; SOLOMON AR; CAVALLO T; TAYLOR RS; RUDLOFF HB; SCHMALSTIEG EJ; DANIELS JC THALIDOMIDE EFFECTS IN BEHCETS-SYNDROME AND PUSTULAR VASCULITIS | 25 | 57 |
| 166 | 27 | 42 | 1124 1994 BONE MARROW TRANSPLANTATION 14(6):937-942 COLE CH; ROGERS PCJ; PRITCHARD S; PHILLIPS G; CHAN KW THALIDOMIDE IN THE MANAGEMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE IN CHILDREN FOLLOWING BONE-MARROW TRANSPLANTATION | 25 | 30 |
| 167 | 5 | 25 | 1178 1995 BRITISH JOURNAL OF CANCER 72(2):339-343 CHING LM; XU ZF; GUMMER BH; PALMER BD; JOSEPH WR; BAGULEY BC EFFECT OF THALIDOMIDE ON TUMOR-NECROSIS-FACTOR PRODUCTION AND ANTITUMOR-ACTIVITY INDUCED BY 5,6-DIMETHYLXANTHENONE-4-ACETIC ACID | 25 | 41 |
| 168 | 0 | 0 | 1188 1995 DRUG SAFETY 12(6):364-369 SCHULER U; EHNINGER G THALIDOMIDE - RATIONALE FOR RENEWED USE IN IMMUNOLOGICAL DISORDERS | 25 | 36 |
| 169 | 8 | 16 | 1302 1997 AIDS RESEARCH AND HUMAN RETROVIRUSES 13(4):301-304 Alexander LN; Wilcox CM A prospective trial of thalidomide for the treatment of HIV-associated idiopathic esophageal ulcers | 25 | 32 |
| 170 | 10 | 20 | 1616 2000 ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE 127(2):171-174 Flageul B; Wallach D; Cavelier-Balloy B; Bachelez H; Carsuzaa F; Dubertret L Thalidomide and thrombosis. | 25 | 27 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 171 | 6 | 18 | 128 1962 LANCET 1(7242):1270-& SMITHELLS RW THALIDOMIDE AND MALFORMATIONS IN LIVERPOOL | 24 | 47 |
| 172 | 2 | 6 | 953 1987 TRANSPLANTATION PROCEEDINGS 19(1):2658-2661 VOGELSANG GB; HESS AD; GORDON G; BRUNDRETTE R; SANTOS GW THALIDOMIDE INDUCTION OF BONE-MARROW TRANSPLANTATION TOLERANCE | 24 | 32 |
| 173 | 6 | 9 | 1071 1992 NEW ENGLAND JOURNAL OF MEDICINE 327(3):208-209 RYAN J; COLMAN J; PEDERSEN J; BENSON E THALIDOMIDE TO TREAT ESOPHAGEAL ULCER IN AIDS | 24 | 33 |
| 174 | 5 | 13 | 1255 1996 CLINICAL INFECTIOUS DISEASES 23(3):501-503 Soler RA; Howard M; Brink NS; Gibb D; Tedder RS; Nadal D Regression of AIDS-related Kaposi's sarcoma during therapy with thalidomide | 24 | 31 |
| 175 | 36 | 174 | 1629 2000 BIOCHEMICAL PHARMACOLOGY 59(12):1489-1499 Stephens TD; Bunde CJW; Fillmore BJ Mechanism of action in thalidomide teratogenesis | 24 | 36 |
| 176 | 7 | 27 | 1936 2001 HAEMATOLOGICA 86(4):399-403 Palumbo A; Giaccone L; Bertola A; Pregno P; Bringhen S; Rus C; Triolo S; Gallo E; Pileri A; Boccadoro M Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma | 24 | 37 |
| 177 | 16 | 33 | 466 1968 JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS 160(1):189-& SCHUMACHER H; BLAKE DA; GURIAN JM; GILLETTE JR A COMPARISON OF TERATOGENIC ACTIVITY OF THALIDOMIDE IN RABBITS AND RATS | 23 | 45 |
| 178 | 29 | 41 | 1084 1993 ARCHIVES OF DERMATOLOGY 129(10):1261-1264 THOMAS L; DUCROS B; SECCHI T; BALME B; MOULIN G SUCCESSFUL TREATMENT OF ADULTS LANGERHANS CELL HISTIOCYTOSIS WITH THALIDOMIDE - REPORT OF 2 CASES AND LITERATURE-REVIEW | 23 | 40 |
| 179 | 5 | 32 | 1384 1997 RESPIRATORY MEDICINE 91(1):31-39 Tavares JL; Wangoo A; Dilworth P; Marshall B; Kotecha S; Shaw RJ Thalidomide reduces tumour necrosis factor-alpha production by human alveolar macrophages | 23 | 38 |
| 180 | 21 | 27 | 1451 1998 JOURNAL OF PHARMACY AND PHARMACOLOGY 50(12):1409-1416 Eriksson T; Bjorkman S; Roth B; Bjork H; Hoglund P Hydroxylated metabolites of Thalidomide: Formation in-vitro and in-vivo in man | 23 | 24 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 181 | 4 | 6 | 1769 2000 NEW ENGLAND JOURNAL OF MEDICINE 343(13):972-973 Rajkumar SV; Gertz MA; Witzig TE Life-threatening toxic epidermal necrolysis with thalidomide therapy for myeloma. | 23 | 33 |
| 182 | 8 | 17 | 1906 2001 CLINICAL CANCER RESEARCH 7(7):1888-1893 Figg WD; Dahut W; Duray P; Hamilton M; Tompkins A; Steinberg SM; Jones E; Premkumar A; Linehan WM; Floeter MK; Chen CC; Dixon S; Kohler DR; Kruger EA; Gubish E; Pluda JM; Reed E A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer | 23 | 58 |
| 183 | 5 | 21 | 1937 2001 HAEMATOLOGICA 86(4):404-408 Hus M; Dmoszynska A; Soroka-Wojtaszko M; Jawniak D; Legiec W; Ciepnuch H; Hellmann A; Wolska-Smolen T; Skotnicki A; Manko J; Polish Multiple Myeloma Study Grp Thalidomide treatment of resistant or relapsed multiple myeloma patients | 23 | 35 |
| 184 | 0 | 0 | 115 1962 LANCET 1(7223):271-& LENZ W THALIDOMIDE AND CONGENITAL ABNORMALITIES - REPLY | 22 | 47 |
| 185 | 0 | 0 | 127 1962 LANCET 1(7239):1128-& PLIESS G THALIDOMIDE AND CONGENITAL ABNORMALITIES | 22 | 37 |
| 186 | 1 | 7 | 146 1962 LANCET 2(7260):812-& ROATH S; ISRAELS MCG; ELVES MW EFFECT OF THALIDOMIDE ON LEUCOCYTE CULTURES | 22 | 30 |
| 187 | 0 | 0 | 154 1962 LANCET 2(7265):1116-& KING CTG; KENDRICK FJ TERATOGENIC EFFECTS OF THALIDOMIDE IN SPRAGUE DAWLEY RAT | 22 | 48 |
| 188 | 8 | 14 | 328 1965 CLINICAL PHARMACOLOGY & THERAPEUTICS 6(3):292-& OLSON KB; HALL TC; HORTON J; KHUNG CL; HOSLEY HF THALIDOMIDE (N-PHTHALOYLGLUTAMIMIDE) IN TREATMENT OF ADVANCED CANCER | 22 | 26 |
| 189 | 4 | 19 | 612 1975 HAUTARZT 26(1):1-5 SHESKIN J THERAPEUTIC EFFECTS OF THALIDOMIDE IN LEPROSY REACTION | 22 | 25 |
| 190 | 2 | 12 | 947 1987 JOURNAL OF CHROMATOGRAPHY-BIOMEDICAL APPLICATIONS 413:181-187 CZEJKA MJ; KOCH HP DETERMINATION OF THALIDOMIDE AND ITS MAJOR METABOLITES BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY | 22 | 23 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 191 | 14 | 21 | 1312 1997 ANTIMICROBIAL AGENTS AND CHEMOTHERAPY 41(12):2797-2799 Piscitelli SC; Figg WD; Hahn B; Kelly G; Thomas S; Walker RE Single-dose pharmacokinetics of thalidomide in human immunodeficiency virus-infected patients | 22 | 25 |
| 192 | 13 | 25 | 1328 1997 CLINICAL INFECTIOUS DISEASES 24(6):1223-1227 Haslett P; Tramontana J; Burroughs M; Hempstead M; Kaplan G Adverse reactions to thalidomide in patients infected with human immunodeficiency virus | 22 | 30 |
| 193 | 10 | 28 | 1567 1999 JOURNAL OF NEURO-ONCOLOGY 43(2):109-114 Moreira AL; Friedlander DR; Shif B; Kaplan G; Zagzag D Thalidomide and a thalidomide analogue inhibit endothelial cell proliferation in vitro | 22 | 36 |
| 194 | 0 | 10 | 1787 2000 SEMINARS IN HEMATOLOGY 37(1):22-25 Alexanian R; Weber D Thalidomide for resistant and relapsing myeloma | 22 | 26 |
| 195 | 68 | 87 | 1924 2001 EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY 57(5):365-376 Eriksson T; Bjorkman S; Hoglund P Clinical pharmacology of thalidomide | 22 | 32 |
| 196 | 10 | 17 | 446 1968 AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY 100(7):952-& GUSDON JP; COHEN C EFFECT OF THALIDOMIDE ON ANTIBODY RESPONSE | 21 | 22 |
| 197 | 18 | 25 | 800 1983 ARCHIVES OF DERMATOLOGY 119(10):812-815 HASPER MF CHRONIC CUTANEOUS LUPUS-ERYTHEMATOSUS - THALIDOMIDE TREATMENT OF 11 PATIENTS | 21 | 32 |
| 198 | 7 | 21 | 805 1983 BRITISH JOURNAL OF DERMATOLOGY 108(4):467-471 LOVELL CR; HAWK JLM; CALNAN CD; MAGNUS IA THALIDOMIDE IN ACTINIC PRURIGO | 21 | 41 |
| 199 | 0 | 0 | 917 1986 CLINICAL RHEUMATOLOGY 5(3):365-371 HAMZA MH TREATMENT OF BEHCETS-DISEASE WITH THALIDOMIDE | 21 | 39 |
| 200 | 19 | 41 | 929 1986 MUSCLE & NERVE 9(9):837-844 LAGUENY A; ROMMEL A; VIGNOLLY B; TAIEB A; VENDEAUDBUSQUET M; DOUTRE MS; JULIEN J THALIDOMIDE NEUROPATHY - AN ELECTROPHYSIOLOGIC STUDY | 21 | 28 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 201 | 3 | 3 | 1021 1990 LANCET 335(8701):1343-1343 GORIN I; VILETTE B; GEHANNO P; ESCANDE JP THALIDOMIDE IN HYPERALGIC PHARYNGEAL ULCERATION OF AIDS | 21 | 31 |
| 202 | 37 | 61 | 1114 1994 ADVERSE DRUG REACTIONS AND TOXICOLOGICAL REVIEWS 13(2):65-76 DARCY PF; GRIFFIN JP THALIDOMIDE REVISITED | 21 | 26 |
| 203 | 20 | 52 | 1192 1995 EXPERIMENTAL HEMATOLOGY 23(9):978-985 FERNANDEZ LP; SCHLEGEL PG; BAKER J; CHEN YF; CHAO NJ DOES THALIDOMIDE AFFECT IL-2 RESPONSE AND PRODUCTION | 21 | 21 |
| 204 | 4 | 22 | 1268 1996 IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY 18(1):59-72 Shannon EJ; Sandoval F Thalidomide can be either agonistic or antagonistic to LPS evoked synthesis of TNF-alpha by mononuclear cells | 21 | 24 |
| 205 | 53 | 74 | 1343 1997 INTERNATIONAL JOURNAL OF DERMATOLOGY 36(12):881-887 Calderon P; Anzilotti M; Phelps R Thalidomide in dermatology. New indications for an old drug | 21 | 26 |
| 206 | 6 | 28 | 1390 1997 TUBERCLE AND LUNG DISEASE 78(1):47-55 Moreira AL; Tsenova-Berkova L; Wang J; Laochumroonvorapong P; Freeman S; Freedman VH; Kaplan G Effect of cytokine modulation by thalidomide on the granulomatous response in murine tuberculosis | 21 | 46 |
| 207 | 20 | 25 | 1735 2000 JOURNAL OF BIOCHEMICAL AND MOLECULAR TOXICOLOGY 14(3):140-147 Teo SK; Sabourin PJ; O'Brien K; Kook KA; Thomas SD Metabolism of thalidomide in human microsomes, cloned human cytochrome P-450 isozymes, and Hansen's disease patients | 21 | 21 |
| 208 | 61 | 96 | 1785 2000 SEMINARS IN HEMATOLOGY 37(1):5-14 Stirling DI Pharmacology of thalidomide | 21 | 23 |
| 209 | 70 | 112 | 2034 2002 ANNUAL REVIEW OF MEDICINE 53:629-657 Richardson P; Hideshima T; Anderson K Thalidomide: Emerging role in cancer medicine | 21 | 34 |
| 210 | 2 | 2 | 230 1963 LANCET 1(728):552-& BOYLEN JB; JOHNSON WJ; HORNE HH TERATOGENIC EFFECTS OF THALIDOMIDE AND RELATED SUBSTANCES | 20 | 33 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 211 | 3 | 7 | 290 1964 LIFE SCIENCES 3(9):987-992 FABRO S; SCHUMACHER H; SMITH RL; WILLIAMS RT TERATOGENIC ACTIVITY OF THALIDOMIDE AND RELATED COMPOUNDS | 20 | 34 |
| 212 | 0 | 0 | 773 1982 ANNALES DE PEDIATRIE 29(1):67-69 VENENCIE PY; SAURAT JH PYODERMA GANGRENOSUM IN A CHILD - TREATMENT WITH THALIDOMIDE | 20 | 36 |
| 213 | 11 | 26 | 1035 1990 TRANSPLANTATION 49(1):20-25 TAMURA F; VOGELSANG GB; REITZ BA; BAUMGARTNER WA; HERSKOWITZ A COMBINATION THALIDOMIDE AND CYCLOSPORINE FOR CARDIAC ALLOGRAFT-REJECTION - COMPARISON WITH COMBINATION METHYLPREDNISOLONE AND CYCLOSPORINE | 20 | 26 |
| 214 | 1 | 9 | 1145 1994 JOURNAL OF CHROMATOGRAPHY A 666(1-2):235-240 KNOCHE B; BLASCHKE G INVESTIGATIONS ON THE IN-VITRO RACEMIZATION OF THALIDOMIDE BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY | 20 | 31 |
| 215 | 3 | 23 | 1155 1994 NEPHRON 67(3):270-273 SILVA SRB; VIANA PCF; LUGON NV; HOETTE M; RUZANY F; LUGON JR THALIDOMIDE FOR THE TREATMENT OF UREMIC PRURITUS - A CROSSOVER RANDOMIZED DOUBLE-BLIND TRIAL | 20 | 43 |
| 216 | 11 | 31 | 1191 1995 EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY 49(1-2):1-6 HARLAND CC; STEVENTON GB; MARSDEN JR THALIDOMIDE INDUCED NEUROPATHY AND GENETIC-DIFFERENCES IN DRUG-METABOLISM | 20 | 23 |
| 217 | 3 | 15 | 1202 1995 JOURNAL OF INFECTIOUS DISEASES 172(4):1137-1140 PETERSON PK; HU SX; SHENG WS; KRAVITZ FH; MOLITOR TW; CHATTERJEE D; CHAO CC THALIDOMIDE INHIBITS TUMOR-NECROSIS-FACTOR-ALPHA PRODUCTION BY LIPOPOLYSACCHARIDE-STIMULATED AND LIPOARABINOMANNAN-STIMULATED HUMAN MICROGLIAL CELLS | 20 | 32 |
| 218 | 5 | 14 | 1234 1996 ANNALS OF THE RHEUMATIC DISEASES 55(11):833-836 Huizinga TWJ; Dijkmans BAC; vanderVelde EA; Kraan TCTMV; Verweij CL; Breedveld FC An open study of pentoxyfylline and thalidomide as adjuvant therapy in the treatment of rheumatoid arthritis | 20 | 37 |
| 219 | 12 | 21 | 1345 1997 INTERNATIONAL JOURNAL OF ONCOLOGY 10(5):965-969 Nguyen M; Tran C; Barsky S; Sun JR; McBride W; Pegram M; Pietras R; Love S; Glaspy J Thalidomide and chemotherapy combination: Preliminary results of preclinical and clinical studies | 20 | 26 |
| 220 | 4 | 13 | 1409 1998 BIOORGANIC & MEDICINAL CHEMISTRY LETTERS 8(19):2669-2674 Muller GW; Shire MG; Wong LM; Corral LG; Patterson RT; Chen YX; Stirling DI Thalidomide analogs and PDE4 inhibition | 20 | 31 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 221 | 2 | 5 | 1753 2000 LANCET 356(9229):566-567 Govindarajan R; Heaton KM; Broadwater R; Zeitlin A; Lang NP; Hauer-Jensen M Effect of thalidomide on gastrointestinal toxic effects of irinotecan | 20 | 27 |
| 222 | 6 | 20 | 2219 2002 JOURNAL OF CLINICAL ONCOLOGY 20(1):302-306 Motzer RJ; Berg W; Ginsberg M; Russo P; Vuky J; Yu R; Bacik J; Mazumdar M Phase II trial of thalidomide for patients with advanced renal cell carcinoma | 20 | 34 |
| 223 | 4 | 22 | 335 1965 HUMANGENETIK 1(6):516-536 NOWACK E CORRELATION BETWEEN THE PERIOD OF THALIDOMIDE-ADMINISTRATION AND EMBRYOPATHY | 19 | 40 |
| 224 | 4 | 7 | 772 1982 ACTA DERMATO-VENEREOLOGICA 62(5):449-450 BAHMER FA; ZAUN H; LUSZPINSKI P THALIDOMIDE TREATMENT OF RECURRENT ERYTHEMA MULTIFORME | 19 | 25 |
| 225 | 2 | 2 | 808 1983 BRITISH MEDICAL JOURNAL 287(6395):799-800 BOWERS PW; POWELL RJ EFFECT OF THALIDOMIDE ON OROGENITAL ULCERATION | 19 | 25 |
| 226 | 1 | 7 | 936 1986 TRANSPLANTATION PROCEEDINGS 18(4):904-906 VOGELSANG GB; TAYLOR S; GORDON G; HESS AD THALIDOMIDE, A POTENT AGENT FOR THE TREATMENT OF GRAFT-VERSUS-HOST DISEASE | 19 | 27 |
| 227 | 2 | 2 | 974 1988 LANCET 2(8620):1135-1135 MCCARTHY DM; KANFER E; TAYLOR J; BARRETT AJ THALIDOMIDE FOR GRAFT-VERSUS-HOST DISEASE | 19 | 21 |
| 228 | 7 | 14 | 1017 1990 JOURNAL OF INTERNAL MEDICINE 228(4):405-407 LARSSON H TREATMENT OF SEVERE COLITIS IN BEHCETS-SYNDROME WITH THALIDOMIDE (CG-217) | 19 | 34 |
| 229 | 44 | 53 | 1489 1999 ARCHIVES OF DERMATOLOGY 135(9):1079-1087 Duong DJ; Spigel GT; Moxley RT; Gaspari AA American experience with low-dose thalidomide therapy for severe cutaneous lupus erythematosus | 19 | 28 |
| 230 | 12 | 15 | 1562 1999 JOURNAL OF CLINICAL PHARMACOLOGY 39(11):1162-1168 Teo SK; Colburn WA; Thomas SD Single-dose oral pharmacokinetics of three formulations of thalidomide in healthy male volunteers | 19 | 19 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 231 | 3 | 12 | 1893 2001 BRITISH JOURNAL OF HAEMATOLOGY 115(3):605-608 Neben K; Moehler T; Kraemer A; Benner A; Egerer G; Ho AD; Goldschmidt H Response to thalidomide in progressive multiple myeloma is not mediated by inhibition of angiogenic cytokine secretion | 19 | 29 |
| 232 | 12 | 56 | 1909 2001 CLINICAL CANCER RESEARCH 7(11):3349-3355 Fujita J; Mestre JR; Zeldis JB; Subbaramaiah K; Dannenberg AJ Thalidomide and its analogues inhibit lipopolysaccharide-mediated induction of cyclooxygenase-2 | 19 | 29 |
| 233 | 15 | 35 | 2199 2002 HAEMATOLOGICA 87(4):408-414 Tosi P; Zamagni E; Cellini C; Ronconi S; Patriarca F; Ballerini F; Musto P; Di Raimondo F; Ledda A; Lauria F; Masini L; Gobbi M; Vacca A; Ria R; Cangini D; Tura S; Baccarani M; Cavo M Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma | 19 | 28 |
| 234 | 0 | 0 | 131 1962 LANCET 2(7246):100-& SPENCER KEV THALIDOMIDE AND CONGENITAL ABNORMALITIES | 18 | 31 |
| 235 | 0 | 1 | 232 1963 LANCET 1(728):723-& WILLIAMS RT TERATOGENIC EFFECTS OF THALIDOMIDE AND RELATED SUBSTANCES | 18 | 39 |
| 236 | 4 | 6 | 347 1965 NATURE 208(5016):1208-& FABRO S; SMITH RL; WILLIAMS RT THALIDOMIDE AS A POSSIBLE BIOLOGICAL ACYLATING AGENT | 18 | 30 |
| 237 | 6 | 12 | 505 1970 JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS 173(2):265-& SCHUMACHER HJ; WILSON JG; TERAPANE JF; ROSEDALE SL THALIDOMIDE - DISPOSITION IN RHESUS MONKEY AND STUDIES OF ITS HYDROLYSIS IN TISSUES OF THIS AND OTHER SPECIES | 18 | 20 |
| 238 | 3 | 8 | 661 1977 TERATOLOGY 16(3):333-335 SCOTT WJ; FRADKIN R; WILSON JG NON-CONFIRMATION OF THALIDOMIDE INDUCED TERATOGENESIS IN RATS AND MICE | 18 | 32 |
| 239 | 0 | 2 | 776 1982 ARCHIVES OF DERMATOLOGY 118(11):875-875 TORRAS H; LECHA M; MASCARO JM THALIDOMIDE TREATMENT OF RECURRENT NECROTIC GIANT MUCOCUTANEOUS APHTHAE AND APHTHOSIS | 18 | 24 |
| 240 | 3 | 13 | 1019 1990 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 23(3):523-525 RADEFF B; KUFFER R; SAMSON J RECURRENT APHTHOUS ULCER IN PATIENT INFECTED WITH HUMAN-IMMUNODEFICIENCY-VIRUS - SUCCESSFUL TREATMENT WITH THALIDOMIDE | 18 | 30 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 241 | 9 | 11 | 1250 1996 BRITISH MEDICAL JOURNAL 313(7054):377-378 Powell RJ New roles for thalidomide | 18 | 24 |
| 242 | 37 | 60 | 1433 1998 EXPERIMENTAL HEMATOLOGY 26(3):217-221 Or R; Feferman R; Shoshan S Thalidomide reduces vascular density in granulation tissue of subcutaneously implanted polyvinyl alcohol sponges in guinea pigs | 18 | 24 |
| 243 | 2 | 6 | 1679 2000 BONE MARROW TRANSPLANTATION 25(12):1319-1320 Zomas A; Anagnostopoulos N; Dimopoulos MA Successful treatment of multiple myeloma relapsing after high-dose therapy and autologous transplantation with thalidomide as a single agent | 18 | 32 |
| 244 | 12 | 44 | 1743 2000 JOURNAL OF INFECTIOUS DISEASES 181(3):954-965 Bekker LG; Haslett P; Maartens G; Steyn L; Kaplan G Thalidomide-induced antigen-specific immune stimulation in patients with human immunodeficiency virus type 1 and tuberculosis | 18 | 27 |
| 245 | 16 | 37 | 1883 2001 BRITISH JOURNAL OF CANCER 85(7):953-958 Stebbing J; Benson C; Eisen T; Pyle L; Smalley K; Bridle H; Mak I; Sapunar F; Ahern R; Gore ME The treatment of advanced renal cell cancer with high-dose oral thalidomide | 18 | 30 |
| 246 | 5 | 12 | 1887 2001 BRITISH JOURNAL OF HAEMATOLOGY 113(2):422-424 Blade J; Perales M; Rosinol L; Tuset M; Montoto S; Esteve O; Cobo F; Villela L; Rafel M; Nomdedeu B; Montserrat E Thalidomide in multiple myeloma: lack of response of soft-tissue plasmacytomas | 18 | 19 |
| 247 | 6 | 48 | 2004 2001 SEMINARS IN HEMATOLOGY 38(3):250-259 Barlogie B; Zangari M; Spencer T; Fassas A; Anaissie E; Badros A; Cromer J; Tricot G Thalidomide in the management of multiple myeloma | 18 | 31 |
| 248 | 0 | 0 | 14 1961 BRITISH MEDICAL JOURNAL 1(521):130-& BURLEY D IS THALIDOMIDE TO BLAME | 17 | 19 |
| 249 | 3 | 7 | 262 1963 SCIENCE 139(356):1295-& LUCEY JF; BEHRMAN RE THALIDOMIDE - EFFECT UPON PROGNANCY IN RHESUS MONKEY | 17 | 37 |
| 250 | 6 | 15 | 422 1967 BIOCHEMICAL JOURNAL 104(2):565-& FABRO S; SMITH RL; WILLIAMS RT FATE OF [14C]THALIDOMIDE IN PREGNANT RABBIT | 17 | 20 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 251 | 47 | 105 | 541 1972 ACTA PHARMACEUTICA SUECICA 9(6):521-542 JONSSON NA CHEMICAL STRUCTURE AND TERATOGENIC PROPERTIES .3. REVIEW OF AVAILABLE DATA ON STRUCTURE-ACTIVITY RELATIONSHIPS AND MECHANISM OF ACTION OF THALIDOMIDE ANALOGS | 17 | 26 |
| 252 | 6 | 20 | 771 1982 ACTA DERMATO-VENEREOLOGICA 62(4):321-324 HASPER MF; KLOKKE AH THALIDOMIDE IN THE TREATMENT OF CHRONIC DISCOID LUPUS-ERYTHEMATOSUS | 17 | 23 |
| 253 | 8 | 13 | 839 1984 ACTA DERMATO-VENEREOLOGICA 64(5):412-417 WINKELMANN RK; CONNOLLY SM; DOYLE JA; PADILHAGONCALVES A THALIDOMIDE TREATMENT OF PRURIGO NODULARIS | 17 | 27 |
| 254 | 20 | 38 | 1023 1990 LEUKEMIA RESEARCH 14(5):395-399 WOOD PMD; PROCTOR SJ THE POTENTIAL USE OF THALIDOMIDE IN THE THERAPY OF GRAFT-VERSUS-HOST DISEASE - A REVIEW OF CLINICAL AND LABORATORY INFORMATION | 17 | 26 |
| 255 | 1 | 20 | 1048 1991 LEUKEMIA RESEARCH 15(2-3):129-136 HATFILL SJ; FESTER ED; DEBEER DP; BOHM L INDUCTION OF MORPHOLOGICAL-DIFFERENTIATION IN THE HUMAN LEUKEMIC-CELL LINE K562 BY EXPOSURE TO THALIDOMIDE METABOLITES | 17 | 20 |
| 256 | 11 | 14 | 1168 1995 ANNALS OF CLINICAL BIOCHEMISTRY 32:79-83 BOUGHTON BJ; SHEEHAN TMT; WOOD J; OBRIEN D; BUTLER M; SIMPSON A; HALE KA HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC ASSAY OF PLASMA THALIDOMIDE - STABILIZATION OF SPECIMENS AND DETERMINATION OF A TENTATIVE THERAPEUTIC RANGE FOR CHRONIC GRAFT-VERSUS-HOST DISEASE | 17 | 17 |
| 257 | 31 | 50 | 1325 1997 CLINICAL AND EXPERIMENTAL IMMUNOLOGY 110(2):151-154 McHugh SM; Rowland TL Thalidomide and derivatives: immunological investigations of tumour necrosis factor-alpha (TNF-alpha) inhibition suggest drugs capable of selective gene regulation | 17 | 32 |
| 258 | 12 | 21 | 1340 1997 IMMUNOPHARMACOLOGY 36(1):9-15 Shannon EJ; Sandoval F; Krahenbuhl JL Hydrolysis of thalidomide abrogates its ability to enhance mononuclear cell synthesis of IL-2 as well as its ability to suppress the synthesis of TNF-alpha | 17 | 18 |
| 259 | 2 | 3 | 1362 1997 JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION 25(2):250-251 Odeka EB; Miller V Thalidomide in oral Crohn's disease refractory to conventional medical treatment | 17 | 0 |
| 260 | 23 | 108 | 1370 1997 MEDICAL HYPOTHESES 49(2):123-131 McCarty MF Thalidomide may impede cell migration in primates by down-regulating integrin beta-chains: Potential therapeutic utility in solid malignancies, proliferative retinopathy, inflammatory disorders, neointimal hyperplasia, and osteoporosis | 17 | 31 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 261 | 8 | 29 | 1378 1997 NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY 356(5):529-535 Dunzendorfer S; Schratzberger P; Reinisch N; Kahler CM; Wiedermann CJ Effects of thalidomide on neutrophil respiratory burst, chemotaxis, and transmigration of cytokine-and endotoxin-activated endothelium | 17 | 23 |
| 262 | 13 | 23 | 1424 1998 CHIRALITY 10(3):223-228 Eriksson T; Bjorkman S; Roth B; Fyge A; Hoglund P Enantiomers of thalidomide: Blood distribution and the influence of serum albumin on chiral inversion and hydrolysis | 17 | 28 |
| 263 | 11 | 41 | 1793 2000 TERATOLOGY 61(3):189-195 Stephens TD; Fillmore BJ Hypothesis: Thalidomide embryopathy - Proposed mechanism of action | 17 | 30 |
| 264 | 4 | 23 | 2058 2002 BLOOD 100(4):1168-1171 Zangari M; Siegel E; Barlogie B; Anaissie E; Saghafifar F; Fassas A; Morris C; Fink L; Tricot G Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy | 17 | 31 |
| 265 | 3 | 8 | 242 1963 LANCET 2(730):405-& LINDAHLKIESSLIN.K; BOOK JA EFFECTS OF THALIDOMIDE ON HUMAN LEUCOCYTE CULTURES | 16 | 23 |
| 266 | 10 | 19 | 398 1966 LANCET 1(7449):1240-& BORE PJ; SCOTHORN.RJ EFFECT OF THALIDOMIDE ON SURVIVAL OF SKIN HOMOGRAFTS IN RABBITS | 16 | 18 |
| 267 | 5 | 22 | 500 1970 CLINICAL AND EXPERIMENTAL IMMUNOLOGY 7(2):241-& COULSON AS; SUMMERS LJ; LINDAHLK.K; TUCKER D; HELLMANN K EFFECT OF 2 SOLUBLE THALIDOMIDE DERIVATIVES ON LYMPHOCYTE STIMULATION | 16 | 17 |
| 268 | 5 | 8 | 742 1981 ARCHIVES OF DERMATOLOGICAL RESEARCH 271(2):165-170 KNOP J; HAPPLE R; BONSMANN G; VAKILZADEH F; MACHER E TREATMENT OF CHRONIC DISCOID LUPUS-ERYTHEMATOSUS WITH THALIDOMIDE | 16 | 17 |
| 269 | 2 | 7 | 982 1988 TERATOLOGY 38(3):221-226 KELSEY FO THALIDOMIDE UPDATE - REGULATORY ASPECTS | 16 | 28 |
| 270 | 63 | 106 | 1003 1990 ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE 117(4):313-321 REVUZ J THALIDOMIDE | 16 | 21 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 271 | 9 | 13 | 1085 1993 ARCHIVES OF DERMATOLOGY 129(12):1548-1550 HOLM AL; BOWERS KE; MCMEEKIN TO; GASPARI AA CHRONIC CUTANEOUS LUPUS-ERYTHEMATOSUS TREATED WITH THALIDOMIDE | 16 | 19 |
| 272 | 3 | 4 | 1128 1994 BRITISH MEDICAL JOURNAL 308(6944):1635-1636 MCBRIDE WG THALIDOMIDE MAY BE A MUTAGEN | 16 | 22 |
| 273 | 12 | 24 | 1169 1995 ANNALS OF THORACIC SURGERY 59(2):277-282 UTHOFF K; ZEHR KJ; GAUDIN PB; KUMAR P; CHO PW; VOGELSANG G; HRUBAN RH; BAUMGARTNER WA; STUART RS THALIDOMIDE AS REPLACEMENT FOR STEROIDS IN IMMUNOSUPPRESSION AFTER LUNG TRANSPLANTATION | 16 | 18 |
| 274 | 4 | 25 | 1236 1996 ANTICANCER RESEARCH 16(6B):3673-3677 Gutman M; Szold A; Ravid A; Lazauskas T; Merimsky O; Klausner JM Failure of thalidomide to inhibit tumor growth and angiogenesis in vivo | 16 | 23 |
| 275 | 8 | 24 | 1420 1998 BRITISH JOURNAL OF CANCER 78(3):336-343 Ching LM; Browne WL; Tchernegovski R; Gregory T; Baguley BC; Palmer BD Interaction of thalidomide, phthalimide analogues of thalidomide and pentoxifylline with the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid: concomitant reduction of serum tumour necrosis factor-alpha and enhancement of anti-tumour activity | 16 | 26 |
| 276 | 3 | 8 | 1490 1999 ARTHRITIS AND RHEUMATISM 42(3):580-581 Breban M; Gombert B; Amor B; Dougados M Efficacy of thalidomide in the treatment of refractory ankylosing spondylitis | 16 | 53 |
| 277 | 7 | 42 | 1521 1999 BRITISH JOURNAL OF CANCER 79(1):114-118 Verheul HMW; Panigrahy D; Yuan J; D'Amato RJ Combination oral antiangiogenic therapy with thalidomide and sulindac inhibits tumour growth in rabbits | 16 | 31 |
| 278 | 9 | 24 | 1615 2000 AMERICAN JOURNAL OF PATHOLOGY 156(1):151-158 Sauer H; Gunther J; Hescheler J; Wartenberg M Thalidomide inhibits angiogenesis in embryoid bodies by the generation of hydroxyl radicals | 16 | 33 |
| 279 | 17 | 32 | 1623 2000 ANTIMICROBIAL AGENTS AND CHEMOTHERAPY 44(9):2286-2290 Verbon A; Juffermans NP; Speelman P; van Deventer SJH; ten Berge IJM; Guchelaar HJ; van der Poll T A single oral dose of thalidomide enhances the capacity of lymphocytes to secrete gamma interferon in healthy humans | 16 | 17 |
| 280 | 49 | 95 | 1701 2000 CURRENT OPINION IN ONCOLOGY 12(6):564-573 Thomas DA; Kantarjian HM Current role of thalidomide in cancer treatment | 16 | 40 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 281 | 18 | 27 | 1728 2000 INTERNATIONAL JOURNAL OF DERMATOLOGY 39(5):383-388 Walchner M; Meurer M; Plewig G; Messer G Clinical and immunologic parameters during thalidomide treatment of lupus erythematosus | 16 | 27 |
| 282 | 6 | 16 | 1810 2001 ANNALS OF ONCOLOGY 12(7):987-990 Bertolini F; Mingrone W; Alietti A; Ferrucci PF; Cocorocchio E; Peccatori F; Cineri S; Mancuso P; Corsini C; Burlini A; Zucca E; Martinelli G Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis. Analysis of clinical results and of surrogate angiogenesis markers | 16 | 26 |
| 283 | 7 | 22 | 1959 2001 JOURNAL OF CLINICAL ONCOLOGY 19(16):3596-3601 Dimopoulos MA; Zomas A; Viniou NA; Grigoraki V; Galani E; Matsouka C; Economou O; Anagnostopoulos N; Panayiotidis P Treatment of Waldenstrom's macroglobulinemia with thalidomide | 16 | 27 |
| 284 | 54 | 61 | 2043 2002 BIOMEDICINE & PHARMACOTHERAPY 56(1):4-12 Singhal S; Mehta J Thalidomide in cancer | 16 | 20 |
| 285 | 13 | 41 | 356 1965 TOXICOLOGY AND APPLIED PHARMACOLOGY 7(2):268-& FRATTA ID; SIGG EB; MAIORANA K TERATOGENIC EFFECTS OF THALIDOMIDE IN RABBITS RATS HAMSTERS AND MICE | 15 | 34 |
| 286 | 14 | 20 | 385 1966 JOURNAL OF PATHOLOGY AND BACTERIOLOGY 91(2):511-& FABRO S; SMITH RL TERATOGENIC ACTIVITY OF THALIDOMIDE IN RABBIT | 15 | 24 |
| 287 | 0 | 32 | 402 1966 MONATSHEFTE FUR CHEMIE UND VERWANDTE TEILE ANDERER WISSENSCHAFTEN 97(6):1648-& KOCH H; KOTLAN J THALIDOMIDE ANALOGUES | 15 | 25 |
| 288 | 11 | 51 | 542 1972 ACTA PHARMACEUTICA SUECICA 9(6):543-562 JONSSON NA CHEMICAL STRUCTURE AND TERATOGENIC PROPERTIES .4. OUTLINE OF A CHEMICAL HYPOTHESIS FOR TERATOGENIC ACTION OF THALIDOMIDE | 15 | 27 |
| 289 | 3 | 9 | 697 1979 HAUTARZT 30(7):376-379 SHESKIN J; YAAR I MOTOR CONDUCTIVITY OF CUBITAL NERVES IN PATIENTS WITH LEPRA REACTION - EXPERIENCE OF 13 YEARS DURING THALIDOMIDE-TREATMENT | 15 | 17 |
| 290 | 9 | 24 | 845 1984 BIOCHEMICAL PHARMACOLOGY 33(9):1471-1477 BRAUN AG; WEINREB SL TERATOGEN METABOLISM - ACTIVATION OF THALIDOMIDE AND THALIDOMIDE ANALOGS TO PRODUCTS THAT INHIBIT THE ATTACHMENT OF CELLS TO CONCANAVALIN A COATED PLASTIC SURFACES | 15 | 24 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 291 | 0 | 4 | 939 1987 ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE 114(11):1387-1389 GNASSIA AM; GNASSIA RT; BONVALET D; PUISSANT A; GOUDAL H HISTIOCYTOSIS-X WITH VULVAR LOCALIZATION - DRAMATIC EFFECT OF THALIDOMIDE | 15 | 23 |
| 292 | 15 | 23 | 989 1989 BIOMEDICINE & PHARMACOTHERAPY 43(9):693-697 MCCARTHY DM; KANFER EJ; BARRETT AJ THALIDOMIDE FOR THE THERAPY OF GRAFT-VERSUS-HOST DISEASE FOLLOWING ALLOGENEIC BONE-MARROW TRANSPLANTATION | 15 | 17 |
| 293 | 0 | 12 | 1136 1994 CHIRALITY 6(4):221-224 KNOCHE B; BLASCHKE G STEREOSELECTIVITY OF THE IN-VITRO METABOLISM OF THALIDOMIDE | 15 | 19 |
| 294 | 5 | 21 | 1244 1996 BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS 224(2):426-430 Miyachi H; Azuma A; Hioki E; Iwasaki S; Kobayashi Y; Hashimoto Y Inducer-specific bidirectional regulation by thalidomide and phenylphthalimides of tumor necrosis factor-alpha production | 15 | 25 |
| 295 | 18 | 41 | 1422 1998 CHEMICAL RESEARCH IN TOXICOLOGY 11(12):1521-1528 Reist M; Carrupt PA; Francotte E; Testa B Chiral inversion and hydrolysis of thalidomide: Mechanisms and catalysis by bases and serum albumin, and chiral stability of teratogenic metabolites | 15 | 17 |
| 296 | 11 | 33 | 1452 1998 JOURNAL OF RHEUMATOLOGY 25(5):964-969 Oliver SJ; Cheng TP; Banquerigo ML; Brahn E The effect of thalidomide and 2 analogs on collagen induced arthritis | 15 | 31 |
| 297 | 1 | 3 | 1678 2000 BLOOD 96(12):4007-4007 Tefferi A; Elliott MA Serious myeloproliferative reactions associated with the use of thalidomide in myelofibrosis with myeloid metaplasia | 15 | 23 |
| 298 | 20 | 27 | 1751 2000 JOURNAL OF RHEUMATOLOGY 27(6):1429-1433 Ordi-Ros J; Cortes F; Cucurull E; Mauri M; Bujan S; Vilardell M Thalidomide in the treatment of cutaneous lupus refractory to conventional therapy | 15 | 28 |
| 299 | 13 | 35 | 1907 2001 CLINICAL CANCER RESEARCH 7(9):2675-2681 Neben K; Moehler T; Egerer G; Kraemer A; Hillengass J; Benner A; Ho AD; Goldschmidt H High plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myeloma | 15 | 29 |
| 300 | 10 | 40 | 2005 2001 SEMINARS IN ONCOLOGY 28(4):62-66 Figg WD; Arlen P; Gulley J; Fernandez P; Noone M; Fedenko K; Hamilton M; Parker C; Kruger EA; Pluda J; Dahut WL A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer | 15 | 37 |
Page 1: 1 2 3 4 5 6 7 8 9
Generated by: HistCite(Vlad).
Version: 2004.09.22